Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
10x Genomics, Inc. TXG
$52.12
-$0.51 (-0.97%)
На 18:01, 12 мая 2023
-4.07%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
5852284793.00000000
-
week52high
56.22
-
week52low
23.81
-
Revenue
516409000
-
P/E TTM
-35992
-
Beta
1.75315400
-
EPS
-1.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 20:30
Описание компании
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Sell | Neutral | 18 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 10 авг 2022 г. |
| William Blair | Market Perform | Outperform | 15 июл 2022 г. |
| Cowen & Co. | Outperform | Outperform | 15 июл 2022 г. |
| B of A Securities | Underperform | Neutral | 15 июл 2022 г. |
| Goldman Sachs | Sell | Sell | 13 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 04 ноя 2022 г. |
| Deutsche Bank | Buy | 14 дек 2022 г. | |
| UBS | Neutral | 02 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hindson Benjamin J. | D | 12972 | 34266 | 14 дек 2022 г. |
| Hindson Benjamin J. | A | 251979 | 34266 | 14 дек 2022 г. |
| Saxonov Serge | D | 747 | 1740 | 13 дек 2022 г. |
| Saxonov Serge | D | 38035 | 3000 | 12 дек 2022 г. |
| Saxonov Serge | A | 911656 | 3000 | 12 дек 2022 г. |
| McAnear Justin J. | D | 76764 | 288 | 22 ноя 2022 г. |
| McAnear Justin J. | D | 77052 | 652 | 22 ноя 2022 г. |
| McAnear Justin J. | D | 77704 | 686 | 22 ноя 2022 г. |
| Hindson Benjamin J. | D | 217713 | 1087 | 22 ноя 2022 г. |
| Hindson Benjamin J. | D | 218800 | 915 | 22 ноя 2022 г. |
Новостная лента
3 CRISPR Stocks to Buy Now Or You'll Be Kicking Yourself Later
InvestorPlace
02 февр 2023 г. в 12:58
CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR, to try to improve human health.
Cathie Wood Is Crushing It This Year Thanks To 9 Stocks
Investors Business Daily
20 янв 2023 г. в 08:00
Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.
10x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
PRNewsWire
19 янв 2023 г. в 16:05
PLEASANTON, Calif. , Jan. 19, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 after market close on Wednesday, February 15, 2023.
3 Medical Info Systems Stocks Braving Industry-wide Headwinds
Zacks Investment Research
17 янв 2023 г. в 05:17
Zacks Medical Info Systems industry stocks like 10x Genomics (TXG), NextGen Healthcare (NXGN) and Health Catalyst (HCAT) are expected to gain as COVID-19 severity fades.
10x Genomics toolkit ‘at the fulcrum of innovation,' CEO says
Yahoo Finance
14 янв 2023 г. в 05:00
This segment originally aired on January 10, 2023. 10x Genomics CEO Serge Saxonov joins Yahoo Finance live anchor Rachell Akuffo to discuss biotechnology innovation, progress in genomics, and macroeconomic headwinds.